X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will support the research and development studies of InMed’s cannabinoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases.
Lead Product(s): INM-900
Therapeutic Area: Neurology Product Name: INM-900
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: NSERC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding November 16, 2022
Details:
Company intends to use the proceeds to continue pipeline development of its candidates including INM-755, advance manufacturing of cannabinoids and cannabinoid analog, support intellectual property development, commercial activities, and for general working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 13, 2022
Details:
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baymedica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
In the peer-reviewed study, researchers analyzed the effects of rare INM-755 (cannabinol) THCV, CBC, cannabigerol (“CBG”) and cannabigerolic acid (“CBGA”) on the major endocannabinoid system elements in skin cells.
Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
delta 9-dominant tetrahydrocannabivarin, d9-THCV is the naturally-occurring variant found in the Cannabis plant, to create unique health and wellness products.
Lead Product(s): Tetrahydrocannabivarin
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baymedica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The Company intends to use the net proceeds from the offerings to continue pipeline development including INM-755 (cannabinol), advance commercial activities and for general working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 06, 2022
Details:
The Company intends to use the net proceeds from the offerings to continue pipeline development including INM-755 having cannabinol, advance commercial activities and for general working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 02, 2022
Details:
Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid, tetrahydrocannabinol (“THC”).
Lead Product(s): Tetrahydrocannabivarin
Therapeutic Area: Nutrition and Weight Loss Product Name: d9-THCV
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radicle Science
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of L’Aquila
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
